ADVENTRX Pharmaceuticals

Latest Headlines

Latest Headlines

Adventrx shares nosedive on FDA rejection, accusations of bungled study

The FDA has rejected Adventrx's Pharmaceuticals' ($ANX) application for a reformulated chemotherapy after regulators accused researchers of bungling a bioequivalence study. While the developer

Adventrx shares slip after FDA hands back NDA

Regulators have handed back Adventrx's NDA for a new formulation of Taxotere, saying the developer needs to perform a study that proves the new drug is biologically equivalent to the original. The

Adventrx to acquire SynthRx in all-stock deal

San Diego-based Adventrx Pharmaceuticals has entered a definitive agreement to acquire SynthRx, a private biotechnology company developing a purified form of a rheologic and antithrombotic agent,

Adventrx announces $22.5M capital raise, mulls acquisition

Adventrx Pharmaceuticals has agreed to sell equity to RA Capital Management and other healthcare-related investors for a per unit purchase price of $2.75, representing gross proceeds of about $22.5

San Diego biotechs see increased revenue

San Diego-based biotech firms have weathered the recent economic downturn by cutting both employees and underperforming drug development programs. The city's public biotechs saw their net loss

Adventrx on the rise after near-death experience

The last time we checked in with Adventrx Pharmaceuticals, the San Diego-based firm was in what appeared to be its death throes. It had cut all but two of its staff, suspended its development

Adventrx goes skeletal as it searches for a rescue

A struggling Adventrx is cutting down to a skeleton staff, suspending its remaining development activities and concentrating all its attention on deal-making. Adventrx's remaining staff is being

Adventrx sheds staffs, hunts for partners

Struggling Adventrx Pharmaceuticals says that it has cut more than half of its workers since the beginning of the fourth quarter last year as it scrambles to preserve cash. And it's also cut back on

Adventrx touts talks as it pursues strategic options

Add San Diego-based Adventrx to the list of biotech companies mulling strategic options. Those options include the sale of one or more of its development programs, finding a merger partner or "other

Adventrx slashes staff and refocuses in restructuring

San Diego-based Adventrx Pharmaceuticals has cut about a quarter of its workforce and announced the departure of its CEO as the developer concentrates on filing an NDA for its two lead programs. All